Mission Statement, Vision, & Core Values of Myomo, Inc. (MYO)

You're looking at Myomo, Inc. (MYO), a company whose mission to restore function for individuals with upper-limb paralysis is backed by a projected $40 million to $42 million in 2025 revenue, an increase of more than 23% over the prior year. That's a serious growth trajectory for a medical robotics firm, but how do their foundational principles-Mission Statement, Vision, and Core Values-drive that financial performance, especially when they reported a $3.7 million net loss in the third quarter of 2025? It's a classic innovator's dilemma: balancing the patient-centric vision of restoring independence with the hard reality of the bottom line. Does their core value of relentless innovation truly translate into a sustainable business model, and what does the growing patient pipeline of 1,669 individuals mean for future revenue conversion?

Myomo, Inc. (MYO) Overview

You're looking for a clear, no-nonsense assessment of Myomo, Inc.'s trajectory, and the takeaway is simple: the company is executing on its strategy to diversify revenue streams while maintaining significant top-line growth, projecting a full-year 2025 revenue of up to $42 million. They're building a more scalable business model, but you must watch the gross margin pressure.

Myomo, Inc. was founded in 2004, commercializing technology originally developed at the Massachusetts Institute of Technology (MIT) to address upper limb paralysis. Their core product is the MyoPro, a myoelectric-controlled upper limb orthosis-a powered brace-that detects a patient's own electromyography (EMG) signals to restore function to a weakened or paralyzed arm. This device is a game-changer for people suffering from conditions like stroke, brachial plexus injury, or spinal cord injury, letting them perform daily activities with greater independence.

The company sells its devices through a direct-billing channel to patients, as well as through Orthotics and Prosthetics (O&P) providers and international distributors, particularly in Germany. This multi-channel approach is defintely a key strategic pivot. If you want to dive deeper into the business model, you can read more about Myomo, Inc. (MYO): History, Ownership, Mission, How It Works & Makes Money.

2025 Financial Performance and Growth Drivers

The latest financial reports, released in November 2025, show a company hitting its stride in revenue generation, even as it manages profitability challenges. For the third quarter of 2025 (Q3 2025), Myomo reported revenue of $10.1 million, which came in at the high end of their expectations and surpassed analyst estimates. This was a 10% increase year-over-year, driven by a 16% rise in the number of MyoPro units delivered, totaling 186 units.

Here's the quick math on their year-to-date performance: Revenue for the first nine months of 2025 reached $29.6 million, marking a substantial 44% increase over the same period in 2024. The full-year 2025 revenue guidance has been reiterated in the range of $40 million to $42 million, which represents an increase of more than 23% over the prior year. That's solid growth.

The growth is diversifying, which is a good sign for long-term stability. International revenue, primarily from Germany, hit a record $1.8 million in Q3 2025, an increase of 63%. Also, the O&P channel revenue reached a quarterly record of $900,000, surging 154% year-over-year. This shift toward recurring referral sources like the O&P channel and the new MyoConnect program is designed to lower the overall patient acquisition cost over time. The patient pipeline also grew to 1,669 candidates as of September 30, 2025, up 32% from a year ago. You want to see that pipeline keep expanding.

A Leader in Wearable Medical Robotics

Myomo is positioning itself as a leader in the specialized field of wearable medical robotics for upper limb paralysis, and the technology backs up the claim. The MyoPro is currently the only marketed device in the U.S. that uses a patient's own muscle signals to restore function. This unique myoelectric sensing capability gives the company a strong competitive moat in the orthotics market.

While the market for powered upper limb orthoses is competitive, Myomo is ranked 2nd among over 150 active competitors in the broader sector, demonstrating a strong market presence. The company's consistent focus on securing reimbursement-including coverage under Medicare Part B-is a critical factor in its success, helping to unlock a massive patient population in the US. This regulatory and reimbursement expertise, plus the unique technology, is why Myomo is a company you need to track closely.

Myomo, Inc. (MYO) Mission Statement

You want to know what drives a company like Myomo, Inc. beyond the quarterly earnings report, and honestly, the mission statement is the blueprint for their long-term value. For Myomo, the core purpose is clear: restoring movement and independence to individuals affected by neurological disorders. This isn't just feel-good language; it's the strategic principle that guides every product decision, from research and development (R&D) spending to their reimbursement strategy.

Their mission is centered around developing and offering innovative medical solutions that improve the quality of life for patients with conditions like stroke, spinal cord injury, and brachial plexus injury. Myomo aims to empower these individuals to regain functional use of their limbs, enhance their mobility, and participate more fully in daily activities. This focus is why the company is projecting full-year 2025 revenue guidance of $40 million to $42 million, an increase of more than 23% versus 2024, because the market need for this kind of life-changing technology is huge. You can dive deeper into the financial mechanics of this growth in Breaking Down Myomo, Inc. (MYO) Financial Health: Key Insights for Investors.

Component 1: Restoring Movement and Independence

The first, most tangible component of the mission is the commitment to restoring movement. This is the direct action that Myomo's flagship product, the MyoPro orthosis (a powered brace for the upper extremity), delivers. It's a literal translation of their purpose into a product that reads faint electromyography (EMG) signals from the skin to move a paralyzed or weakened arm and hand. Think of it as a direct link between a patient's intention and a functional movement.

This isn't an abstract goal; it's a measurable outcome. In the third quarter of 2025 alone, Myomo recognized revenue on 186 MyoPro units, demonstrating a steady cadence of delivering this core promise to patients. The average selling price (ASP) for one of these custom-fabricated devices was approximately $54,200 in Q3 2025, reflecting the high value and customization of the technology. The business model is built on this core value proposition. If the device didn't restore function, they defintely wouldn't see that kind of unit volume.

Component 2: Innovative Medical Solutions

To deliver the first component consistently, Myomo must be relentlessly focused on innovation. They are a wearable medical robotics company, and staying on the cutting edge is an operational imperative, not just a marketing slogan. Their technology was originally pioneered in the labs of the Massachusetts Institute of Technology (MIT), and they continue to invest in R&D to maintain their market leadership position.

Here's the quick math on their commitment: they launched two key product upgrades in early 2025-the MARK 2 clinical unit and the MyoPro 2x-which are designed to enhance patient independence and support daily functional tasks. This continuous product development is essential to address the unique and evolving needs of patients. Also, the company is actively expanding its network of trained providers; by the end of Q1 2025, they had trained more than 300 Certified Prosthetists and Orthotists (CPOs), a significant increase from 160 at the start of the year, ensuring the innovative product is fitted and supported correctly.

Component 3: Improving Quality of Life

The final component acknowledges that Myomo's work extends far beyond physical rehabilitation. Improving quality of life encompasses the emotional, social, and psychological well-being of their patients. Regaining the ability to perform activities of daily living (ADLs), like feeding oneself or reaching for an object, has a profound impact on self-esteem and social participation.

The impact is quantifiable through clinical research. A study published in the Journal of NeuroEngineering and Rehabilitation found that patients who used Myomo's myoelectric orthoses experienced a 40% improvement in upper-extremity function compared to those who received traditional rehabilitation therapy alone. That's a huge difference in a patient's daily life. Furthermore, Myomo is focused on expanding access to make this quality-of-life improvement available to more people. Medicare Part B patients represented 54% of their third quarter 2025 revenue, showing their success in navigating the complex reimbursement landscape to serve a critical patient population.

Myomo, Inc. (MYO) Vision Statement

You need to know what drives Myomo, Inc. (MYO) beyond the quarterly earnings call. Their vision is clear: to become the worldwide standard of care for individuals with upper-limb paralysis. This isn't just a feel-good statement; it's a tangible market goal that maps directly to their operational strategy, especially in light of their projected 2025 revenue of $40 million to $42 million.

The vision translates into a mandate for aggressive market penetration and technological superiority. It means displacing older, passive orthotics with their powered MyoPro device, which uses myoelectric signals to restore function. They're aiming for a dominant position, not just a niche one. Honestly, this kind of ambition requires continuous capital deployment and a defintely solid reimbursement strategy.

The worldwide standard of care means global scale.

The Mission: Restoring Movement and Independence

Myomo's mission centers on restoring movement and independence to individuals affected by neurological disorders. This is the core purpose, the 'why' behind the MyoPro's development. It's about getting people back to daily activities like feeding themselves or carrying objects, which is a massive quality-of-life improvement.

The tangible proof of this mission is in the number of devices reaching patients. In the third quarter of 2025 alone, Myomo recognized revenue on 186 MyoPro units, a 16% increase over the same period last year. That's 186 people regaining significant arm and hand function in just three months. To be fair, the average selling price (ASP) was approximately $54,200 per unit in Q3 2025, which underscores the high value and complexity of these innovative medical solutions. The mission isn't cheap, but the impact is profound.

• Restore lost motor function.
• Offer innovative medical technologies.
• Improve emotional and psychological well-being.

Core Value: Driving Reimbursement and Market Reach

A core value that directly impacts the bottom line is driving reimbursement and expanding market reach. A medical device, no matter how good, is useless if patients can't afford it. So, securing favorable insurance coverage is a non-negotiable strategic objective.

The company has made significant strides here, which is a key reason for their strong 2025 revenue projections. They now have in-network contracts covering 35 million private payer lives, up from previous periods. Plus, Medicare Part B patients represented 54% of their Q3 2025 revenue, showing the success of their advocacy and coverage efforts. This focus on the payer landscape is what allows them to reiterate their full-year 2025 revenue guidance of $40 million to $42 million, a growth of over 23% compared to 2024. Here's the quick math: more covered lives equals more revenue units. Breaking Down Myomo, Inc. (MYO) Financial Health: Key Insights for Investors

Core Value: Patient-Centric Innovation and Partnership

Innovation and patient-centricity are two sides of the same coin for Myomo. They are committed to continuous technological advancement to enhance device functionality and user experience. This is evident in their product upgrades and their growing focus on the MyoConnect clinical referral program.

The MyoConnect platform and the expansion of the Orthotics and Prosthetics (O&P) channel are central to lowering the customer acquisition cost and improving pipeline quality. Revenue from the O&P channel more than doubled year-over-year in Q3 2025, showing that their strategy of building partnerships with healthcare providers is working. What this estimate hides, however, is the ongoing need to manage cash burn; even with year-to-date revenue at $29.6 million through September 30, 2025, the company's Adjusted EBITDA was a negative $2.7 million for Q3 2025, meaning they are still investing heavily to scale. Still, the focus is on a scalable path to sustainable profitability by diversifying revenue streams in 2026.

Myomo, Inc. (MYO) Core Values

You're looking for the true north of Myomo, Inc., the principles that drive their financial and operational decisions. Honestly, a company's core values are where the rubber meets the road; they translate into real-world initiatives that either boost revenue or burn cash. For Myomo, the guiding principles-derived directly from their mission to restore function for individuals with upper-limb paralysis-center on three critical pillars: Patient-Centricity, Innovation, and Clinical Excellence. These values aren't just posters on a wall; they are directly linked to the company's projected $40 million to $42 million in revenue for the 2025 fiscal year, representing an increase of more than 23% over 2024. That's the quick math on why values matter.

If you want a deeper dive into the company's foundation, you can check out Myomo, Inc. (MYO): History, Ownership, Mission, How It Works & Makes Money.

Patient-Centricity: Restoring Independence

Patient-Centricity means putting the user's independence first, which for Myomo, Inc. translates into relentless efforts to expand access to the MyoPro orthosis. The MyoPro is a myoelectric-controlled upper extremity orthosis, which is a fancy term for a powered arm brace that reads faint muscle signals to restore functional use of a paralyzed limb. The core value here is simple: if patients can't get the device, the mission fails.

The company's commitment to this value is defintely visible in their 2025 payer access work. In the third quarter of 2025 alone, Myomo, Inc. successfully secured in-network coverage that now extends to approximately 35 million private payer lives. This expansion is crucial because it lowers the financial hurdle for patients and directly supports the delivery of devices. For instance, the company recognized revenue on 186 MyoPro units in Q3 2025, demonstrating that expanded access results in tangible patient impact.

• Expanded access to 35 million private payer lives.
• Q3 2025 saw 186 MyoPro units delivered.
• Focus is on enabling patients to perform daily tasks like feeding themselves.

Innovation: Advancing Neuro-Robotics

Innovation is the lifeblood of a medical robotics company, and for Myomo, Inc., it means constantly refining the technology and the patient acquisition model. The MyoPro itself is a product of innovation, based on patented technology developed at MIT and Harvard Medical School. It remains the only device of its kind that uses a patient's own neurological signals (EMG signals) to power movement. That's a huge competitive moat.

In 2025, the company launched a significant strategic initiative called MyoConnect. This platform is designed to shift patient lead generation away from expensive advertising toward a more scalable, referral-based system with therapists and physicians. The early results are encouraging: the new program helped contribute to a sequential decline in the cost per pipeline add of 5% in the third quarter of 2025. This operational innovation is a clear action taken to uphold the value of advancing their business model as much as their product.

Clinical Excellence: Quality and Trust

Clinical Excellence is the non-negotiable standard in medical devices; it's about providing a product that is effective, safe, and reliable, meeting the highest standard of quality. Without this, insurance coverage and physician referrals-the core of their business-would dry up.

The company demonstrates this value through its financial performance, which reflects the market's trust in the MyoPro's quality. For the nine months ended September 30, 2025, Myomo, Inc.'s year-to-date gross margin stood at 64.6%. A high gross margin like this, even with fluctuations, indicates a premium, high-value product that commands a strong average selling price (ASP), which was approximately $54,200 in Q3 2025. This sustained financial metric shows that the market-patients and payers-is willing to pay for the clinical results delivered by a high-quality, reliable device. Plus, their MyoPro is referred for patients at over twenty VA hospitals and major centers like the Mayo Clinic. You can't buy that kind of clinical endorsement; you have to earn it.